The Compulsory Licensing in Russia: The First Precedent Lessons Learned
Abstract
The compulsory license mechanism in Russia had been described in the Civil Code of the Russian Federation for a long time. However, there had been no real cases of granting of compulsory licensing till recently. In 2018 the Russian court first time in history approved for use within the territory of Russia the compulsory license of the drug Revlimid® (INN lenalidomide) protected by the patent of Celgene, an American pharmaceutical company.